Be the first to like.

Share

A gene therapy will be offered for sale in Europe with a money-back guarantee, according to GlaxoSmithKline, the company commercializing it.

The treatment, called Strimvelis, is the first outright cure for a rare disorder to emerge from gene therapy, and its price tag of 594,000 euros ($665,000), announced last week, makes it one of the most expensive one-time treatments ever sold by a drug firm.

Now, we’ve learned, it’s also the first genetic fix to come with a warranty.

… Read More

 

Be the first to like.

Share
MIT Technology Review

Tags: , , , , , , , , , ,

Leave a Reply